These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 21854254)

  • 1. Association between saliva PSA and serum PSA in conditions with prostate adenocarcinoma.
    Shiiki N; Tokuyama S; Sato C; Kondo Y; Saruta J; Mori Y; Shiiki K; Miyoshi Y; Tsukinoki K
    Biomarkers; 2011 Sep; 16(6):498-503. PubMed ID: 21854254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
    Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
    Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
    Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a role for serum human tissue kallikrein in detection of prostate cancer?
    Ochiai A; Shukla A; Davis JW; Fritsche HA; Bhadkamkar V; Babaian RJ
    Urology; 2007 Sep; 70(3):519-22. PubMed ID: 17905108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.
    Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
    Urology; 2004 Mar; 63(3):492-8. PubMed ID: 15028444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advanced prostate cancer with normal serum prostate-specific antigen values].
    Komura T; Yamagiwa K; Ogura H; Kohjimoto Y; Ohkawa T; Inagaki T; Ebisuno S; Senzaki A
    Hinyokika Kiyo; 1998 May; 44(5):303-6. PubMed ID: 9656099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia.
    Sciarra A; Gentile V; Monti S; Dattilo C; Autran Gomez A; Salciccia S; Pannunzi LP; Toscano V; Di Silverio F
    Urol Int; 2008; 80(1):68-73. PubMed ID: 18204237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A.
    Sciarra A; Voria G; Monti S; Mazzone L; Mariotti G; Pozza M; D'Eramo G; Silverio FD
    Prostate; 2004 Mar; 58(4):421-8. PubMed ID: 14968443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate specific antigen as tumor marker: relationship with histologic grading.
    Xess A; Singh M; Raghwendra KH; Sharma HP; Shahi SK
    Indian J Pathol Microbiol; 2001 Jul; 44(3):261-4. PubMed ID: 12024909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSA excess in the differential diagnosis of prostate carcinoma.
    Díaz F; Morell M; Rojo G
    Arch Esp Urol; 1997 May; 50(4):415-8. PubMed ID: 9219422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
    Alessandro S; Vincenzo G; Maria AG; Stefano S; Alessandro G; Salvatore M; Vincenzo T; Franco DS
    Endocr Relat Cancer; 2007 Sep; 14(3):625-32. PubMed ID: 17914093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy.
    Shariat SF; Kattan MW; Song W; Bernard D; Gottenger E; Wheeler TM; Slawin KM
    Cancer Res; 2003 Sep; 63(18):5874-8. PubMed ID: 14522912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma.
    Sciarra A; Di Silverio F; Autran AM; Salciccia S; Gentilucci A; Alfarone A; Gentile V
    Urol Int; 2009; 82(2):147-51. PubMed ID: 19321999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The patients less than 50 years: is there a need to lower the PSA cutoff point?
    Hekal IA
    Prostate Cancer Prostatic Dis; 2009; 12(2):148-51. PubMed ID: 18825164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ratios of free to total prostate-specific antigen and total prostate specific antigen to protein concentrations in saliva and serum of healthy men.
    Ayatollahi H; Darabi Mahboub MR; Mohammadian N; Parizadeh MR; Kianoosh T; Khabbaz Khoob M; Kamalian F
    Urol J; 2007; 4(4):238-41. PubMed ID: 18270950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men.
    Akduman B; Alkibay T; Tuncel A; Bozkirli I
    Can J Urol; 2000 Oct; 7(5):1104-9. PubMed ID: 11114873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
    Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
    J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
    Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
    N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.